Products - Endometrial cancers | Topic | NICE

Showing 8 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency (TA1117)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2025
Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer (TA1092)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 August 2025
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
25 March 2026
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
23 July 2026
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Technologies to improve the detection of endometrial cancer
Status:
Topic prioritisation
Programme:
Health technology evaluation
Expected publication date:
TBC
Technologies to improve detection of endometrial cancer
Status:
Awaiting development
Programme:
Health technology evaluation
Expected publication date:
TBC
Dostarlimab for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency when systemic treatment is suitable [ID6660]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC